Publications by authors named "Julia MeiSSner"

Claim this Profile
F
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.
Justin Ferdinandus, Gundolf Schneider, Alden Moccia, Richard Greil, Mark Hertzberg, Julia Meissner

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients.
Paul J Bröckelmann, Boris Böll, Daniel Molin, Gundolf Schneider, Sirpa Leppä, Julia Meissner

Hemasphere· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial.
Alexander Fosså, Daniel Molin, Paul J Bröckelmann, Gundolf Schneider, Ulf Schnetzke, Julia Meissner

Hemasphere· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
Peter Borchmann, Justin Ferdinandus, Gundolf Schneider, Alden Moccia, Richard Greil, Julia Meissner

Lancet· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Michael Fuchs, Anne Sophie Jacob, Helen Kaul, Carsten Kobe, Georg Kuhnert, Julia Meissner

Leukemia· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of Secondary Plant Metabolites and Micronutrients Improves Mitochondrial Function in a Cell Model of Early Alzheimer's Disease.
Lukas Babylon, Julia Meißner, Gunter P Eckert

Int J Mol Sci· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Paul J Bröckelmann, Ina Bühnen, Julia Meissner, Karolin Trautmann-Grill, Peter Herhaus

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation.
Julia Meissner, Michael Schmitt, Mindaugas Andrulis, Leonille Schweizer, Sascha Dietrich

Bone Marrow Transplant· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma.
Anne Sophie Jacob, Helen Kaul, Michael Fuchs, Sarah Gillessen, Stefanie Kreissl, Julia Meissner

Infection· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group.
Carla Damaschin, Helen Goergen, Stefanie Kreissl, Annette Plütschow, Frank Breywisch, Julia Meissner

Leukemia· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients.
Nora Liebers, Claudius Speer, Louise Benning, Peter-Martin Bruch, Isabelle Kraemer, Julia Meissner

Blood· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial.
Mathias Witzens-Harig, Andreas Viardot, Ulrich Keller, Julia Wosniok, Oliver Deuster

Hemasphere· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
Stefanie Kreissl, Helen Goergen, Ina Buehnen, Carsten Kobe, Alden Moccia, Julia Meissner

Lancet Haematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Sarah Gillessen, Annette Plütschow, Michael Fuchs, Jana Markova, Richard Greil, Julia Meissner

Lancet Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Peter Borchmann, Annette Plütschow, Carsten Kobe, Richard Greil, Julia Meissner

Lancet Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.
Lorenz Selberg, Peter Stadtherr, Sascha Dietrich, T Hien Tran, Thomas Luft, Julia Meissner

Bone Marrow Transplant· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial.
Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, Helen Goergen, Horst Müller, Julia Meissner

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Severe Case of Anaplastic Large Cell Lymphoma in a Previously Healthy Woman: Diagnostic and Therapeutic Challenges.
Petya Angelova, Robert Brock, Alexandra-Teodora Negoescu, Lara-Marie Schmitt, Julia Meißner

Prague Med Rep· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group.
Stefanie Kreissl, Horst Müller, Helen Goergen, Julia Meissner, Max Topp

J Clin Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Paul J Bröckelmann, Helen Goergen, Ulrich Keller, Julia Meissner, Rainer Ordemann

JAMA Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.
Bastian von Tresckow, Michelle Fanale, Kirit M Ardeshna, Robert Chen, Julia Meissner

Leuk Lymphoma· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Michael Fuchs, Helen Goergen, Carsten Kobe, Georg Kuhnert, Andreas Lohri, Julia Meissner

J Clin Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.
Stefanie Kreissl, Helen Goergen, Horst Müller, Julia Meissner, Anja Mehnert

Leuk Lymphoma· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.
Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A Eichenauer, Julia Meissner

J Clin Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082, November 2017) - Recommendations and Statements for Girls and Women.
Ralf Dittrich, Sabine Kliesch, Andreas Schüring, Magdalena Balcerek, Dunja M Baston-Büst

Geburtshilfe Frauenheilkd· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis